Vanguard Group Inc Nuvalent, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,412,072 shares of NUVL stock, worth $259 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,412,072

Previous 3,339,850 2.16%

Holding current value

$259 Million

Previous $246 Million 4.24%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$72.35 - $88.99 $5.23 Million - $6.43 Million	72,222 Added 2.16%	3,412,072 $256 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $51.1 Million - $96.8 Million	1,205,668 Added 56.49%	3,339,850 $246 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $615,044 - $783,741	15,722 Added 0.74%	2,134,182 $98.1 Million
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $1.14 Million - $2.15 Million	48,214 Added 2.33%	2,118,460 $89.3 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $1.47 Million - $1.94 Million	57,938 Added 2.88%	2,070,246 $54 Million

Q4 2022 Feb 10, 2023	BUY	$18.46 - $36.37 $10.6 Million - $20.8 Million	571,615 Added 39.68%	2,012,308 $59.9 Million
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $2.45 Million - $3.6 Million	180,528 Added 14.33%	1,440,693 $28 Million
Q2 2022 Aug 12, 2022	SELL	$7.4 - $15.07 $2.79 Million - $5.69 Million	-377,342 Reduced 23.04%	1,260,165 $17.1 Million
Q1 2022 May 13, 2022	BUY	$11.65 - $19.57 $10.2 Million - $17.2 Million	877,835 Added 115.55%	1,637,507 $22.7 Million
Q4 2021 Feb 14, 2022	BUY	$18.01 - $30.1 $192,562 - $321,829	10,692 Added 1.43%	759,672 $14.5 Million
Q3 2021 Nov 12, 2021	BUY	$18.25 - $38.35 $13.7 Million - $28.7 Million	748,980 New	748,980 $16.9 Million

Others Institutions Holding NUVL

# of Institutions

184

Shares Held

54.4M

Call Options Held

838K

Put Options Held

116K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Nuvalent, Inc. Transaction History